Regeneron Pharmaceuticals Aktie News

The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth.

Shares of Regeneron (REGN 0.44%) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal R...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of...

23andMe wants to reopen bidding on its assets after former CEO Anne Wojcicki put together a $305 million offer, topping Regeneron.

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was ...

Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond will usually allow anyone to earn superior returns.

Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.